Pfizer Inc. (NYSE: PFE) Q4 2020 earnings call dated Feb. 02, 2021
Corporate Participants:
Charles E. Triano — Senior Vice President, Investor Relations
Albert Bourla — Chairman and Chief Executive Officer
Mikael Dolsten — Chief Scientific Officer and President, Worldwide Research, Development and Medical
Angela Hwang — Group President, Pfizer Biopharmaceuticals Group
Frank D’Amelio — Chief Financial Officer and Executive Vice President, Global Supply
John Young — Group President, Chief Business Officer
Analysts:
David Risinger — Morgan Stanley — Analyst
Steve Scala — Cowen — Analyst
Gregg Gilbert — Truist Securities — Analyst
Louise Chen — Cantor Fitzgerald — Analyst
Umer Raffat — Evercore — Analyst
Geoffrey Porges — SVB Leerink — Analyst
Vamil Divan — Mizuho — Analyst
Tim Anderson — Wolfe Research — Analyst
Jason Zemansky — Bank of America — Analyst
Ronny Gal — Bernstein — Analyst
Navin Jacob — UBS — Analyst
Chris Schott — JPMorgan — Analyst
_________
To read the full earnings call transcript, click here
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
Listen On
